Zhi Tong Cai Jing·2025-08-12 12:50Core Viewpoint - Fudan Zhangjiang (01349) reported a decline in revenue and profit for the first half of 2025, primarily due to increased R&D expenses and the impact of a previous termination of a partnership with a service provider [1] Financial Performance - Revenue for the period was approximately 390 million yuan, representing a year-on-year decrease of 4.42% [1] - The profit attributable to shareholders was 5.715 million yuan, showing a significant year-on-year decline of 91.89% [1] - Earnings per share were reported at 0.0055 yuan [1] Factors Affecting Performance - The decline in profit was mainly attributed to an increase in R&D expenses compared to the same period last year [1] - The previous year's financials were positively impacted by compensation and penalties received after terminating the partnership with Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd. [1]